Clinical Trials Logo

Colitis clinical trials

View clinical trials related to Colitis.

Filter by:

NCT ID: NCT06331637 Not yet recruiting - Ulcerative Colitis Clinical Trials

Outcomes of Transanal Tran-section and Single-stapled (TTSS) Ileal Pouch-Anal Anastomosis

TTSS-Pouch
Start date: July 31, 2024
Phase:
Study type: Observational

This study aims to compare the functional and surgical outcomes of Ulcerative Colitis (UC) patients undergoing Transanal Transection and Singl-Stapled (TTSS) versus Double-stapled Ileal Pouch-Anal Anastomosis (IPAA)

NCT ID: NCT06324500 Recruiting - Clinical trials for Acute Severe Colitis

Prognostic Role of Bowel Ultrasound Scan in Children Affected by Acute Severe Colitis

Start date: March 2, 2020
Phase:
Study type: Observational

ASC is a life-threatening medical emergency. The lack of a timely intervention has shown to be associated with a mortality rate higher than 20% in adults, whereas a prompt targeted therapy has displayed a decrease of the aforementioned rate to 1%. Therefore, the identification of predictors of poor outcome trough an objective tool may provide crucial help to individualize the timing of second line treatment initiation. At the state of the art, PUCAI represents the only validated tool to appraise the risk of first-line treatment failure and there is a lack of objective methods with a prognostic value in ASC. BUS has proven to be a reliable tool in assessing disease activity in children with UC and it has also shown statistically significant correlation with endoscopic features of disease activity. Given the literature suggesting a role for BUS in severe UC and the results from our retrospective study we aim to validate our findings trough a prospective assessment of the potential prognostic role of BUS in ASC.

NCT ID: NCT06315179 Not yet recruiting - Ulcerative Colitis Clinical Trials

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

STRIDE
Start date: April 2024
Phase:
Study type: Observational [Patient Registry]

This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.

NCT ID: NCT06311123 Recruiting - Ulcerative Colitis Clinical Trials

Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

Start date: October 6, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the mechanism of action of ozanimod in patients with ulcerative colitis (UC). The main questions it aims to answer are: 1. Prospectively assess the effects of ozanimod on the cellular composition of intestinal lamina propria and blood by deep immunophenotyping (CyTOF) of immune cell subsets prior and after the drug's administration. 2. Determine whether changes in cell subsets observed via mass cytometry correlate with with clinical or histologic parameters of disease activity. Colonic biopsies and peripheral blood samples will be collected from patients with UC before and after the onset of ozanimod. Researchers will compare intestinal and peripheral leukocytes before and after the drug's administration.

NCT ID: NCT06306261 Not yet recruiting - Ulcerative Colitis Clinical Trials

Controlling the Mental Health for a Better Response to Treatment in Patients With Ulcerative Colitis

TIMAEUS
Start date: March 15, 2024
Phase:
Study type: Observational

The project aims to implement the Internet Of Thing (IoT) platform of the San Raffaele Hospital (OSR) with data from stress conditions perceived by the patient through the synergistic collaboration between patients, gastroenterologists and psychologists.

NCT ID: NCT06298461 Not yet recruiting - Ulcerative Colitis Clinical Trials

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Start date: March 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare how effective and how tolerable two different bowel preparation laxatives are for colonoscopy. The aim is to compare oral sulfate solution (OSS) to another laxative called 2L polyethylene glycol (PEG) solution to see which is more effective and more tolerable by individuals with IBD (Crohn's disease or Ulcerative colitis).

NCT ID: NCT06294925 Not yet recruiting - Colitis, Ulcerative Clinical Trials

A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis

EFFECT-UC
Start date: April 20, 2024
Phase:
Study type: Observational

The purpose of this real world non-interventional study is to learn about the effects of etrasimod as treatment for patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment choice according to the treating physician. Additionally, patients have to be between 18 and 65 years of age and should not have taken etrasimod in the past. All patients will be prescribed etrasimod according to standard of care. Assessments will be conducted according to standard of care with the exception of health questionnaires which will be completed by the patients online on their own device. The study duration is 52 weeks with 28 days of safety follow-up. Patients will visit their treating physician as they would if they were not enrolled in the study. During the study duration, patients will be asked to complete health questionnaires on a regular basis either on their mobile phone, tablet or computer. The effects of etrasimod will be analyzed for each patient comparing to their disease activity prior to the start of etrasimod.

NCT ID: NCT06290934 Not yet recruiting - Ulcerative Colitis Clinical Trials

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

SWIFT
Start date: March 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to learn if GS-1427 is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with GS-1427 with participants treated with placebo (Part 1), and participants treated with GS-1427 or ustekinumab alone with participants treated with GS-1427 in combination with ustekinumab (Part 2). The primary objectives of this study are: Part 1: To assess the efficacy of GS-1427, compared with placebo control, in achieving clinical response at Week 12 Part 2: To assess the efficacy of combination therapy with GS-1427 and ustekinumab, compared with GS-1427 and ustekinumab monotherapies, in achieving clinical response at Week 12

NCT ID: NCT06281704 Completed - Ulcerative Colitis Clinical Trials

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Start date: November 26, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase Ib clinical study to evaluate the safety, tolerance, pharmacokinetics and efficacy of AK101 in subjects with moderately to severely active ulcerative colitis.

NCT ID: NCT06269185 Recruiting - Ulcerative Colitis Clinical Trials

Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis

Start date: March 6, 2024
Phase:
Study type: Observational

Anti-TNF (tumor necrosing factor) treatment with infliximab (IFX) and adalimumab (ADA) are established first-line biological therapies used in treatment of patients with ulcerative colitis (UC). There are no head-to-head comparative studies between these two drug but meta-analysis of randomized controlled trials states that IFX might be more effective than ADA for the induction of clinical remission. However, several observational studies conclude that ADA seem to have similar effect as IFX in treating patients with UC but these studies have limitations. The overall aim of this retrospective multicenter observational cohort study is to evaluate if there is a difference in efficacy between infliximab (IFX) and adalimumab (ADA) in treating bio-naive patients with UC in the short and long term during the modern era when therapeutic drug monitoring have been used to optimize anti-TNF treatment.